

Product datasheet for **TL302521**

PGPEP1 Human shRNA Plasmid Kit (Locus ID 54858)

Product data:

Product Type:	shRNA Plasmids
Product Name:	PGPEP1 Human shRNA Plasmid Kit (Locus ID 54858)
Locus ID:	54858
Synonyms:	PAP-I; Pcp; PGI; PGP; PGP-I; PGPI
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	PGPEP1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 54858). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	BC042138 , NM_001300927 , NM_001308366 , NM_001329471 , NM_001329476 , NM_001329477 , NM_001329478 , NM_017712 , NR_138029 , NM_017712.1 , NM_017712.2 , NM_017712.3 , NM_001300927.1 , BC042138.1 , BC004942 , BC028063 , NM_017712.4 , NM_001300927.2
UniProt ID:	Q9NXJ5
Summary:	The gene encodes a cysteine protease and member of the peptidase C15 family of proteins. The encoded protein cleaves amino terminal pyroglutamate residues from protein substrates including thyrotropin-releasing hormone and other neuropeptides. Expression of this gene may be downregulated in colorectal cancer, while activity of the encoded protein may be negatively correlated with cancer progression in colorectal cancer patients. Activity of the encoded protease may also be altered in other disease states including in liver cirrhosis, which is associated with reduced protease activity, and in necrozoospermia, which is associated with elevated protease activity. [provided by RefSeq, Jul 2016]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).